# Beijing BeneWill Technology Development Co., Ltd: Phase 3 study in Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD) (25000 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Beijing BeneWill Technology Development Co., Ltd |
| Sponsor type | Academic and hospital |
| Study | Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) |
| NCT ID | NCT07860216 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD) |
| Intervention types | biological |
| Target enrollment | 25000 |
| Site countries | China |
| Posted | 2026-10-06 |
| Planned start | 2026-08-21 |
| Event | Newly registered study |
| Event date | 2026-10-06 |

## Why this score
- Phase 3: multi-site, larger budget.
- 25000 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07860216). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.